{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.45","value":"46.2"}]}],"title":"Baseline (n = 2047)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.97","value":"11.3"}]}],"title":"Week 24 (n = 1992)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.94","value":"10.2"}]}],"title":"Week 48 (n = 1830)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.79","value":"9.0"}]}],"title":"Week 108 (n = 1606)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.44","value":"8.9"}]}],"title":"Week 156 (n = 1509)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.01","value":"8.9"}]}],"title":"Week 204 (n = 1412)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.51","value":"9.7"}]}],"title":"Week 264 (n = 1329)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2067"}],"units":"Participants"}],"description":"Erythrocyte sedimentation rate (ESR) was determined locally.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.","id":"OG000","title":"Tocilizumab"}],"paramType":"MEAN","populationDescription":"All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study. Only participants with available data were included in the analysis.","timeFrame":"Baseline to Week 264","title":"Erythrocyte Sedimentation Rate at Baseline and Weeks 24, 48, 108, 156, 204, and 264","type":"SECONDARY","unitOfMeasure":"mm/h"}